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Introduction: Lung cancer (LC) is the most common cause of cancer death in the world and associated with
significant economic burden. We conducted a review of published literature to identify prognostic factors associated
with LC survival and determine which may be modifiable and could be targeted to improve outcomes.
Methods: The exceptionally large volume of LC prognostic research required a new staged approach to reviewing the
literature. This comprised an initial mapping review of existing reviews or meta-analyses, based on titles and abstracts,
followed by an overview of systematic reviews evaluating factors that independently contribute to lung cancer survival.
The overview of reviews was based on full text papers and incorporated a more in-depth assessment of reviews
evaluating modifiable factors.
Results: A large volume of published systematic reviews and meta-analyses were identified, but very few focused on
modifiable factors for LC survival. Several modifiable factors were identified, which are potential candidates for targeted
interventions aiming to improve cancer outcomes. The mapping review included 398 reviews, of which 207
investigated the independent effect of prognostic factors on lung cancer survival. The most frequently evaluated
factors were novel biomarkers (86 biomarkers in 138 reviews). Only 15 modifiable factors were investigated in 20
reviews. Those associated with significant survival improvement included normal BMI/less weight loss, good performance
status, not smoking/quitting after diagnosis, good pre-treatment quality of life, small gross volume tumour, early-stage
tumour, lung resection undertaken by a thoracic/cardiothoracic surgeon, care being discussed by a multidisciplinary team,
and timeliness of care.
Conclusions: The study utilised a novel approach for reviewing an extensive and complicated body of research evidence.
It enabled us to address a broad research question and focus on a specific area of priority. The staged approach ensured
the review remained relevant to the stakeholders throughout, whilst maintaining the use of objective and transparent
methods. It also provided important information on the needs of future research. However, it required extensive planning,
management, and ongoing reviewer training.
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The prognosis for lung cancer is poor, with a 12% average
5-year survival rate in Europe [1] falling to only 10% in Eng-
land and Wales [1]. However, there is considerable clinical
heterogeneity between the patients comprising the overall
population with lung cancer. If identified early enough, rad-
ical treatment including surgery can provide the best chance
of a cure. Approximately 80% of lung cancers are non-small
cell types, which spread less rapidly than small cell lung
cancer, but still have poor prognosis [2].
A prognostic factor is any measure that is associated
with the risk of future health outcomes in those with exist-
ing disease [3], including sociodemographic factors, pa-
tient characteristics, health seeking behaviours, health
service factors, and clinical characteristics. Genuine prog-
nostic factors can play an important role in pathways to-
wards improved clinical outcomes [4]. They are crucial in
developing treatment plans and providing reliable infor-
mation on prognosis or survival. However, the potential
value of a prognostic factor is dependent on the availabil-
ity of consistent evidence of its prognostic ability across
multiple studies [4].
Prognostic research aims to understand the course, de-
terminants, or probability of outcome in a cohort. In con-
trast, prognostic factor research is more specific and aims
to identify independent factors that might be useful modi-
fiable targets for interventions to improve outcomes,
building blocks for prognostic models, or predictors of dif-
ferential treatment response [4]. Prognostic research is
summarised as four inter-related research themes in a
framework introduced by the PROGnosis RESearch
Strategy (PROGRESS) partnership: theme 1, overall prog-
nosis research, investigates the average prognosis or likely
course of disease [5]; theme 2, prognostic factor research,
explores the independent impact of individual prognostic
factors on lung cancer survival [4]; theme 3, prognostic
model research, aims to develop, validate, or assess the
impact of a statistical model which combines multiple fac-
tors from which the risk of lung cancer survival can be
calculated for individual patients [6]; and finally, theme 4,
stratified medicine research, aims to identify characteris-
tics of patients likely to derive most clinical benefit or least
harm from a specific treatment [7].
We aimed to identify prognostic factors consistently
shown to be associated with lung cancer survival in pub-
lished literature, and determine which factors may be
modifiable and could be targeted to improve survival.
Systematic reviews provide the gold standard approach
for synthesising the evidence as they use standardised
and empirically tested methods to minimise bias and
error. However, the literature on prognostic factors in
lung cancer is increasing exponentially [8], with hun-
dreds of prognostic factors having already been identi-
fied [9]. A comprehensive, in-depth systematic review ofprimary studies was not feasible within a reasonable
timescale. A rapid review approach was therefore devel-
oped based on elements of existing systematic review
methodology and accepted practice [10, 11]. One ap-
proach to developing a summary of the existing evidence
in a short timeframe is to conduct a systematic review
(or overview) of existing reviews [12, 13]. Overviews of
reviews are a relatively new and increasingly popular ap-
proach [14, 15]. Evidence mapping is another new tool
that has been developed for addressing the challenges of
a large evidence base, and belongs to the family of sys-
tematic approaches to reviewing the evidence [16, 17].
The methods for conducting, interpreting, and reporting
overviews of reviews are still in their infancy, and guid-
ance for their conduct is limited [15, 18, 19]. Guidance
is especially limited for the less common types of over-
view, such as those addressing reviews of prognosis or
diagnostic test accuracy [15]. The methodology for con-
ducting systematic reviews of prognostic research is also
still evolving with no accepted guidance on how best to
conduct them [20].
The current review provides an example of the devel-
opment and application of the combined use of these
newly evolving methods for reviewing an extensive body
of research evidence, in this instance on prognostic fac-
tors to inform decision-making. This paper focuses on
the methodological approach used and is intended to in-
form those with an interest in review methods; it does
not provide an in-depth presentation of the findings of
prognostic factors associated with lung cancer.
Methods
Review methods
We conducted a pragmatic review of reviews using a
three-stage approach, as outlined in Table 1. This included
an initial mapping review of the prognostic research (stage
1), an overview of reviews of prognostic factor research
(stage 2), followed by a more in-depth evaluation of modi-
fiable factors (stage 3). The overall approach was guided
by accepted methodological and reporting standards for
systematic reviews [10, 11, 21]. The mapping review was
informed by the methods used by the Evidence for Policy
and Practice Information (EPPI) Centre and the overview
of reviews by guidance for conducting systematic reviews
of prognostic factors [22, 23].
The review team was supported by public health and
clinical stakeholders. The underlying purpose of the
study, which was funded by Public Health Wales
(PHW), was to inform the development of multivariate
modelling of Welsh data proposed by the Welsh Cancer
Intelligence and Surveillance Unit (WCISU). The stake-
holders, in this instance, were therefore the director of
WCISU (DWH) and a Consultant Respiratory Physician
(GC). The stepped approach enabled us to provide
Table 1 Summary of the review process
Stage Elements of the review process
Stage 1: initial systematic mapping
review of prognostic research
A descriptive map of prognostic research for lung cancer survival based on the assessment of titles and
abstracts only.
● Classification of relevant reviews and meta-analysis according to PROGRESS research themes 1–4, lung
cancer type, number and type of prognostic factors investigated, and publication type.
● Identification of all prognostic factors, from which a comprehensive coding scheme was developed.
● Identification of prognostic factors deemed to be potentially modifiable (reviewed by two independent
public health and clinical stakeholders).
Stage 2: overview of systematic
reviews of prognostic factor research
A more in-depth review of a subset of systematic reviews focusing on prognostic factor research
(PROGRESS research theme 2) based on the assessment of full text publications.
● Summary of key data from included reviews.
● Coding of reviews according to the prognostic factors they addressed.
● Summary of all prognostic factors investigated by each review, including whether or not they were
significantly associated with survival†, and the direction of the impact.
Stage 3: in-depth evaluation of
potentially modifiable factors
A more in-depth evaluation of the results of included reviews reporting modifiable factors.
● Summary of the magnitude of the effect of modifiable prognostic factors (where possible).
†The term ‘significant’ denotes statistical significance and refers to the results of either the regression or meta-analyses (pooled analysis) or, where no pooled analysis
was undertaken, to more than 50% of studies in narrative syntheses. For reviews that reported both pooled analysis and narrative synthesis, this was based on the
results of the pooled analysis. Where significant findings were based on only a single study within a review, this was highlighted.
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stage and obtain ongoing feedback on prognostic factors
that were likely to be the most relevant for both the
multivariate model development, and policy and clinical
decision making. The whole review process was also
guided by monthly meetings with the stakeholders.Search strategy
MEDLINE, EMBASE, Cochrane Library, and Web of Sci-
ence were searched in December 2015 using a strategy
based on published prognostic factors search strategies
[24], plus a search filter for systematic reviews and meta-
analyses (Appendix A in Additional file 1) [25]. Searches
were limited to 1990 onwards in order to be clinically and
methodologically relevant [26, 27] but were not limited by
language. All bibliographic data retrieved by the searches
were imported into Endnote X5 and de-duplicated.Table 2 Inclusion criteria
Inclusion criteria
Study design Systematic reviews or meta-analyses.
Target population Patients with a primary diagnosis of lung cancer
reported separately from other cancers.
Type of prognostic
factors (exposure)
Any prognostic or predictive factors relating to
the patient, tumour, socioeconomic position,
or healthcare provider and system were included.
Reviews of single or multiple factors were included
Outcome measure Overall or cancer specific survival.
Language and
publication type
No language restrictions were used during the
searches and mapping review.Selecting studies for inclusion
The titles and abstracts were screened by two independent
reviewers (SN, ZHT, TL, RP), using the criteria outlined in
Table 2. Relevant references were coded according to the
PROGRESS framework theme (stage 1). Articles published
in English that appeared to report systematic reviews of
prognostic factor studies (PROGRESS theme 2) were re-
trieved in full and re-evaluated (RL, MH, ND, SN, MAS,
AH) for inclusion in the subsequent overview of reviews
(stage 2). Disagreements regarding relevance were resolved
by discussion or, if necessary, consulting a third reviewer.
Systematic reviews
Studies were assessed for eligibility as a systematic re-
view based on the eight essential elements outlined in
the Cochrane Handbook [11] and the UK Centre for
Reviews and Dissemination’s (CRD’s) guidance [10].
These include the following:Exclusion criteria and notes
Editorials or commentaries on included reviews.
Meta-analyses not conducted as part of a systematic review
were excluded from the overview of reviews (see text below).
Reviews of mixed cancers were only considered if they
included > 1 lung cancer study, with findings reported separately
from other cancers. Studies of prognostic or predicative factors
for developing lung cancer, in an otherwise healthy population,
were not included.
Lung cancer studies not reporting on histological subtypes were
excluded for the overview of reviews (see text below).
.
The review did not include studies evaluating the effectiveness
of treatments to improve survival. However, predictive factors
of treatment outcomes (PROGRESS theme 4 research) were
considered for inclusion in the mapping review.
–
Non-English language publications and conference abstracts were not
included in the overview of reviews.
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ii. Explicit search criteria
iii. A search of more than one reference database
iv. Pre-defined eligibility criteria for studies
v. Explicit and reproducible methodology
vi. A systematic presentation of the characteristics of
included studies
vii. The assessment for the validity of the findings of
the included studies
viii.A narrative or quantitative synthesis of the included
evidence.
The initial mapping review was based on titles and ab-
stracts only, and therefore, a pragmatic and more liberal
definition of a systematic review was used during this
stage. However, for the purpose of the overview of re-
views, studies had to meet four of the essential criteria
(i, ii, iv, viii) for inclusion. Systematic reviews of prog-
nostic factors may be of inferior quality compared with
reviews of clinical effectiveness and are possibly less
likely to include critical appraisal of included studies. It
was therefore decided to use some of the ‘essential’ ele-
ments (iii, v, vi, vii) as quality, rather than inclusion, cri-
teria. Some studies were retrieved in full during the
initial mapping review in order to check eligibility, as
the reference details were insufficient to make this
judgement. Studies that reported a meta-analysis that
was not based on a systematic search of the literature
were not included in the second stage of the review.
Meta-analysis
Meta-analyses using individual patient data (IPD), where
raw data from multiple studies are synthesised, are con-
sidered the gold standard for synthesising prognostic
factor studies [28, 29]. However, they must be based on
a systematic approach and attempt to include all rele-
vant studies in order to avoid producing biased estimates
or erroneous conclusions. Meta-analyses of IPD includ-
ing only studies from a single research group are un-
likely to include all relevant data and were excluded.
Lung cancer subtypes
Studies reporting on lung cancer as a whole, without
distinguishing histological subtypes, were excluded from
the overview of reviews unless they investigated prog-
nostic factors that stakeholders deemed to be important
and modifiable. Studies that were included in the initial
mapping review and reported on lung cancer as a whole
were first checked to see if they investigated prognostic
factors deemed to be ‘modifiable’ (see the ‘Coding stud-
ies and data extraction’ section below). Those that did
were then presented to the stakeholders to decide
whether they should be included, based on the import-
ance of the modifiable factor.Coding studies and data extraction
As part of the initial mapping review, relevant references
were coded according to the underlying research ques-
tions investigated (prognostic research theme), whether
they aimed to evaluate single or multiple factors and
whether they were published in the English language
(Appendix B in Additional file 2). This coding was under-
taken, using Microsoft Excel, by one reviewer and checked
by a second reviewer (SN, ZHT, TL, RP, RL). The type of
lung cancer and prognostic factors investigated were also
recorded. These data were then used in an iterative man-
ner to develop a comprehensive list of codes for the prog-
nostic factors and lung cancer types. The initial lists were
developed by one reviewer (RL) and checked by a second
(RP). Included prognostic factors were grouped using the
following categorisation or domain headings:
 tumour characteristics (histology);
 clinical characteristics (routinely assessed biological
variables);
 ‘new’ biomarkers (biological factors not used in
routine practice);
 metabolic criteria;
 patient characteristics;
 healthcare provider and system; and
 other.
The data extraction and coding of papers retrieved in
full (stage 2) were conducted by one reviewer (MH, ND,
SN, MAS, AH, RL), with the first 10–15 checked by a
second reviewer (RL, MH). The discrepancies were dis-
cussed at a weekly team meeting, and the instructions
for coding and data extraction updated accordingly. Be-
cause of the complexity of the coding, some additional
ongoing checking was conducted whilst developing sum-
mary tables of the included reviews and summarising
the overall findings. The type of data extracted during
stage 2 is provided in the summary tables presented in
Additional files 3 and 4 (Appendix C and D), and in-
cluded the overall aim; the year in which the searches
were conducted; type of lung cancer and histological
subtypes included; the number and type of prognostic
factors investigated; the number of included studies; the
sample size range; whether included studies were retro-
spective, prospective, or a mixture of both; whether
multivariate analyses were conducted; the type of syn-
thesis and summary measure used; whether additional
analyses were undertaken; results; and author’s conclu-
sions. A further, in-depth evaluation was conducted of
included reviews of modifiable factors, described below.
The data were extracted using Microsoft Access, which
allowed the various codes to be selected from.
The list of prognostic factors developed as part of the
mapping review was assessed by two independent public
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tify those that were deemed to be potentially modifiable.
Quality assessment
The quality of included reviews (in stage 2) was assessed
using eight essential elements of a systematic review [10,
11], whilst reviews that investigated modifiable prognostic
factors were additionally appraised using A Measurement
Tool to Assess Systematic Reviews (AMSTAR) [30].
Synthesis
The findings of existing reviews can be utilised within an
overview of reviews or integrated into a new review in
different ways [31]. The current review represents a
rapid review approach, and as such, we chose not to dis-
aggregate and/or re-analyse the existing review findings.
Rather, we used the complete reviews and combined
their findings in a narrative synthesis.
The findings of the overview of reviews were sum-
marised and analysed using structured tables, listing all
the factors investigated by each review, whether or not
they were significantly associated with survival, and the
direction of impact. Some systematic reviews included a
meta-analysis or meta-regression (pooled analysis), whilst
others only presented a narrative synthesis. Prognostic fac-
tors that were identified as being ‘significantly’ associated
with survival were those that were shown to be statistically
significant in either pooled analysis or by more than 50%
of studies in the narrative synthesis. For reviews that re-
ported both pooled analysis and narrative synthesis, this
was based on the results of the pooled analysis. Pooled
analyses and narrative syntheses were summarised separ-
ately. Where significant findings were based on only a sin-
gle included study within a review, this has been
highlighted. The magnitude of effects was only extracted
for modifiable factors and presented in separate tables.
This included both the summary effect estimate and 95%
confidence intervals from both univariate and multivariate
analysis, where presented.
Results
Mapping review
Database searches identified 4062 references after de-
duplication, of which 398 were eligible for the mapping
review. Of these, 264 were retrieved in full, reassessed,
and re-themed if appropriate; 207 were subsequently in-
cluded in the overview of reviews (Fig. 1). A summary of
the studies included in the mapping review, indicating
the prognostic factors addressed and the type of lung
cancer investigated, is available in the Additional file 2
(Appendix B). The final distribution of included refer-
ences across the four PROGRESS themes was as follows:
theme 1, overall prognosis, n = 12; theme 2, prognostic
factors, n = 299; theme 3, prognostic models, n = 20; andtheme 4, stratified medicine, n = 175 (figures differ from
those in the PRISMA diagram because 102 studies cov-
ered multiple research questions).
Overview of reviews of prognostic factor research
The findings presented here represent a condensed ver-
sion of the results to provide an illustration of the quan-
tity, breadth, and type of data provided by the review.
More details of the included studies are provided in the
additional files.
The overview of reviews included 207 systematic re-
views investigating the independent effect of prognostic
factors on lung cancer survival (theme 2). Reference
details and review characteristics are presented in
Additional file 3 (Appendix C) along with the findings of
the quality assessment.
Most reviews were recent; 105 (51%) had searches
conducted between 2013 and 2015, and only 23 (11%)
prior to 2007. Most (146/207, 71%) limited inclusion to
patients with non-small cell lung cancer (NSCLC); five
(2%) focused on small cell lung cancer (SCLC). Thirty
two (15%) included any type of lung cancer, 21 (10%)
covered multiple cancer sites including lung, one review
limited inclusion to lung squamous cell carcinoma, one
to lung adenocarcinoma, and one included multiple pri-
mary lung cancers. Most (149, 72%) reviews were from
East Asia, 54 (26%) from North America, 33 (16%) from
Europe, three from West Asia, and one from Southeast
Asia. A complete list of prognostic factors and their as-
sociation with survival is presented in Additional file 4
(Appendix D) and summarised in brief below. Three re-
views aimed to identify any prognostic factor associated
with survival for NSCLC and as such included over 50
prognostic factors. The findings of these reviews are
summarised separately in Additional file 5 (Appendix E).
The most frequently evaluated prognostic factors were
‘new’ biomarkers; 86 were investigated in 138 reviews,
although 47 (55%) were each only evaluated in a single
review. Eighteen biomarkers were evaluated by three or
more reviews: EGFR (n = 11), ERCC1 (n = 7), K-RAS
(n = 5), microRNA-155 (n = 5), survivin (n = 5), CXCR4
(n = 4), E-cadherin (n = 4), microRNA-21 (n = 4), p53
(n = 4), CRP (n = 4), COX-2 (n = 3), FGFR1 (n = 3), HER-
2 (n = 3), HIF-1alpha (n = 3), P16 (n = 3), TS (n = 3),
VEGF-C (n = 3). EGFR mutation was not found to be a
significant factor in 7/11 reviews; ERCC1 was associated
with improved survival in chemotherapy patients, but
not for patients receiving surgery alone. Poor survival
was associated with the presence, high levels, or overex-
pression of survivin, K-RAS, p53, microRNA-21,
CXCR4, VEGF-C, TS, P16, HIF-1alpha, and HER-2 and
with reduced E-cadherin levels.
Twenty-one factors relating to tumour characteristics
were investigated in 26 reviews; seven were investigated
Fig. 1 PRISMA flow diagram
Lewis et al. Systematic Reviews           (2019) 8:171 Page 6 of 18
Lewis et al. Systematic Reviews           (2019) 8:171 Page 7 of 18in three or more reviews: circulating tumour cells
(CTCs) (n = 3), histology (n = 6), lymphovascular inva-
sion (LVI) (n = 3), nodal status (n = 4), stage (n = 6), syn-
chronous metastases (n = 3), and visceral pleural
invasion (VPI) (n = 3). Stage is described in more detail
under modifiable factors. The presence of CTCs, positive
VPI, and LVI was found to be associated with signifi-
cantly poorer survival in all reviews evaluating these fac-
tors. Adenocarcinoma was associated with significantly
better survival than squamous cell or other histological
subtypes in four out of five reviews.
Eight reviews evaluated the prognostic value of measuring
the metabolic activity of the primary tumour. Volumetric
parameters evaluated by fluorodeoxyglucose positron emis-
sion tomography, including high values of standardised up-
take value (SUV), metabolic tumour volume, and total
lesion glycolysis were consistently identified as significant
prognostic factors of poor survival in all the reviews.
The survival impact of 11 clinical characteristics or
routinely assessed biological variables was evaluated in
12 reviews, but none by more than two reviews. High or
normal serum albumin and the presence of skin rash as-
sociated with targeted chemotherapy treatment (EGFR
tyrosine kinase inhibitors) were evaluated by two re-
views; both were found to be associated with signifi-
cantly better survival.
Nine patient characteristics were investigated in nine re-
views, five of them in two or more reviews: age (n = 3),
gender (n = 5), performance status (n = 2), pre-treatment
quality of life (n = 2), and smoking status (n = 3). Three
out of five reviews identified male gender, and two out of
three reviews found advanced age to be significant adverse
predictors of survival. The remaining three factors are dis-
cussed in more detail under modifiable factors, along with
BMI, which was only evaluated by one review.
Five factors categorised as ‘healthcare provider and
system’ were investigated in five reviews: insurance sta-
tus, multidisciplinary team (MDT) patient management,
surgical procedural volume, surgeon specialty, and time-
liness of care, all of which are discussed in more detail
under modifiable factors.
Three prognostic factors categorised as ‘other’ were in-
vestigated by four reviews; two were only evaluated in a
single review. Perioperative blood transfusion due to ex-
cessive bleeding, which was evaluated by two reviews, was
found to be significantly associated with poor survival.
Review of modifiable factors
One or both independent clinician and public health stake-
holders identified twenty-eight modifiable prognostic fac-
tors at the mapping stage, summarised in Additional file 6
(Appendix F). However, one included review reported on
body mass index (BMI) and weight loss together so these
two factors were subsequently combined. Twenty reviewsmeeting the criteria for inclusion in the overview of re-
views evaluated one or more modifiable factor, but only 15
factors were investigated by these reviews. (The remaining
12 factors are detailed in Additional file 6.) The included
reviews are distinguished in this next section using their
unique review identification (ID) number presented in
brackets. Three reviews that reported findings for lung
cancer as a whole, without distinguishing subtypes, did not
meet the inclusion criteria but were included based on the
importance and potential usefulness of the prognostic
factor they evaluated, namely surgeon specialty and the an-
nual volume of surgical lung resections for cancer (414),
the presence of tuberculosis (TB) (5789), and duration of
the intervals between presentation and diagnosis or
treatment (722).
A description of the reviews that investigated modifi-
able factors is presented in Table 3. The reviews were
fairly recent, with all but one conducted from 2007 on-
wards. However, five reviews (25%) only searched one
reference database, and five (25%) did not include a
summary of study characteristics. Only seven (35%) re-
views reported conducting a quality assessment of in-
cluded studies. A quality appraisal of the reviews using
the AMSTAR tool is presented in Additional file 7
(Appendix G). Almost half of the reviews (9/20 45%)
were poor quality, and only two (10%) were considered
to be good quality (studies 494 and 695). Most of re-
views did not consider unpublished/grey literature or
studies not published in the English language. Most re-
views did not include an assessment of the scientific
quality of the included studies, and the characteristics of
included studies were also poorly presented with known
prognostic factors, such as age, sex, performance status,
stage, and histology, not generally listed. Half of the re-
views included patients with NSCLC, and six (30%) in-
cluded the broader category of lung cancer, whilst none
limited inclusion to just SCLC. Three reviews (15%) cov-
ered multiple cancer sites, including lung. The 20 modi-
fiable factors investigated by included reviews are
summarised in Table 4. However, as shown in the de-
scription of the prognostic factors, they were often ana-
lysed as multiple subcategories or histological subgroups
with varying thresholds. The total number of prognostic
factors investigated ranged from one to 20 for 17
reviews, whilst the remaining three evaluated ‘any’
prognostic factor associated with survival (Table 3).
(These three reviews (182, 843, 1051) are also described
in more detail in the Additional file 5.) Only eight re-
views reported pooled analyses, using meta-analysis or
meta-regression (Table 3), the results of which are pre-
sented in Additional file 8 (Appendix H). The level of
statistical heterogeneity between included studies, where
investigated, was found to be significant in all but one
review (695). The findings of the remaining reviews were
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the findings were statistically significant or not, or a sys-
tem of ‘vote counting’.
Patient characteristics
Four patient-related modifiable factors were investigated:
BMI, performance status (PS), quality of life (QoL), and
smoking status. These were evaluated in seven reviews,
five of which reported a narrative synthesis, one a meta-
analysis, and one a regression-analysis. Two of the re-
views (1051, 8434) reporting narrative syntheses aimed
to evaluate any prognostic factor associated with survival
and therefore included both a large number of factors
and studies (Tabl 3). One of these reviews (8434) only
reported the total number of included studies that iden-
tified these factors as significant in their multivariate
analysis, without providing the denominators.
Less weight loss or normal BMI at diagnosis was found
to be associated with significantly better survival in ad-
vanced NSCLC, according to 11/21 studies in one review
(5632) and 6 studies in another (which did not report the
denominators) (8434). Four reviews investigated the effect
of PS (by various measures of wellbeing and activities of
daily life) in advanced or metastatic NSCLC. Better PS
was found to be significantly associated with survival in
36/47 studies in one review (5362) and 13 in another
(8434), whilst it was only found to be a significant factor
in 4/13 studies in a third review (1051). The final review
did not find it to be a significant influencing factor associ-
ated with survival extension, but this analysis was based
on first-line chemotherapy trials where the majority of pa-
tients had a good PS (182). Three reviews evaluated pre-
treatment health-related QoL. Two reviews found that
better QoL or fewer symptoms were significantly associ-
ated with increased survival in patients with late stage
NSCLC, according to all six included studies (5362) or
one study (8434). The third review was both poorly con-
ducted and reported, but also found that pre-treatment
(baseline) global quality of life scores or some aspects of
quality of life measures were significant independent pre-
dictors of survival in 24/26 lung cancer studies (703).
Five reviews, including one good quality review (695),
evaluated the effect of smoking status. Two reviews
showed that quitting smoking at or after diagnosis was as-
sociated with better survival than continued smoking in
limited SCLC or early NSCLC, but these findings were
only significant in SCLC (695, 51). Not smoking was also
found to be associated with significantly better survival
than smoking in three reviews (8434, 5362, 51), whilst a
fourth only reported significant findings in 2/23 studies
(1051). One review reported significant findings associated
with ‘less/no smoking status’ and the outcome of advanced
NSCLC in multivariate analysis of 6/9 studies (5362); the
other reported better survival in patients with limitedSCLC who did not smoke during chemo-radiotherapy
treatment in one study, although another study reported
that neither smoking status at time of diagnosis nor pack
years smoked had a significant impact on survival for lim-
ited SCLC (8434); a third study found that smoking status
both before and after surgery was significantly associated
with survival in early NSCLC (51).
Healthcare provider and system
Six modifiable factors that were categorised as healthcare
provider and system were included: insurance status,
multidisciplinary team (MDT) patient management, sur-
geon, procedural volume, and timeliness of care. These
were investigated in five reviews, most of which used a nar-
rative synthesis.
One review from the USA investigated the association
between insurance status and survival in patients with
NSCLC (621). Patients with Medicaid or no insurance
had worse survival, higher incidence rates, and later
stage at diagnosis than those with private or Medicare
insurance, and were also less likely to undergo curative
procedures than those with private, Medicare, or other
funded insurance in 6/9 studies.
One review investigated the impact of MDTs on pa-
tient outcomes (5807). This was a poor quality system-
atic review that considered any cancer type. Patient care
being managed by an MDT was identified as a signifi-
cant factor associated with improved survival in NSCLC,
according to a single study.
Two reviews evaluated the association between time to
diagnosis or treatment, and survival. Both reviews pre-
sented a narrative synthesis based on vote counting. The
patient journey from symptom onset to diagnosis or treat-
ment initiation can be broken down into multiple different
intervals [32]. One review (722) that investigated the ef-
fects of timeliness of care for lung cancer as a whole did
not differentiate between the diagnostic and treatment
interval, whilst the second review (8441), which evaluated
any cancer type, but reported separate data for NSCLC,
did distinguish between interval types (outlined in Table 4).
In the review limited to lung cancer, shorter intervals were
associated with significantly improved survival in three
out of eighteen studies, and reduced survival in four; eight
studies did not report significant findings (722). The sec-
ond review reported that shorter intervals between either
symptom onset or being seen in primary care, and diagno-
sis were associated with improved survival in NSCLC, ac-
cording to a single study (in 1/1 and 1/4 studies,
respectively) (8441). However, shorter intervals between
symptom onset and first being seen in primary care, and
being seen in primary care and starting treatment, were
associated with reduced survival, according to one out of
2 studies. The discordant finings reported by both these
reviews are likely to be due to the ‘waiting time
Lewis et al. Systematic Reviews           (2019) 8:171 Page 14 of 18paradox’ [33–35], where patients with rapidly growing
or metastatic tumours are more likely to experience
symptoms that draw attention to the underlying cancer,
but have poor outcomes.
One review evaluated the effect of both surgeon specialty
and volume of lung resections for cancer in a hospital or
by a surgeon on post-operative mortality or overall survival
(414). Hospitals performing a high-volume of resections
for lung cancer had significantly better outcomes, in terms
of post-operative mortality, than low-volume hospitals, but
there was no significant difference between the two for
overall survival. Surgeon procedural volume showed no
significant effect on post-operative mortality, but general
surgeons had significantly higher mortality risks than gen-
eral thoracic or cardiothoracic surgeons.
Clinical characteristics or routinely assessed biological variables
Two factors categorised as clinical or routinely assessed
biological variables were included: tuberculosis (TB) and
serum vitamin D level. Each factor was only evaluated
by a single review using a narrative synthesis. According
to a very poorly conducted and reported review, the me-
dian survival in patients with active TB was 4months
compared with 8months in patients without TB in one
study (5789). Low serum vitamin D was not found to be
associated with survival in NSCLC, according to both
relevant studies in one good quality review (494).
Tumour characteristics
Nine reviews evaluated stage, and two investigated
tumour volume as prognostic factors for survival. Three
reviews evaluated stage along with other factors in re-
gression analyses. In one review, the regression analyses
were undertaken using IPD obtained from the authors of
the primary studies (105), and in another, IPD were ex-
tracted from the published studies (467).
Tumour stage was identified as a significant factor as-
sociated with overall survival on univariate, but not
multivariate analysis in two of the reviews (105, 467),
and not a significant factor in the multivariate regression
analysis undertaken within the third review (182). A fur-
ther review conducted a series of eight meta-analyses
comparing stages I versus II, I versus III, II versus III,
and III versus IV, in both NSCLC and SCLC. There was
a significant reduction in the relative risk of death for
earlier staged tumours when compared with later stages
in six meta-analyses (923). One review evaluated the
prognostic differences between adenocarcinoma in situ
and minimally invasive adenocarcinoma using a meta-
analysis, and found no significant differences in survival
rates between the two groups (5815). The remaining
four reviews included a narrative synthesis. Three found
that less advanced stage (mainly IIIB) was associated
with significantly better survival than stage IV in themajority of included studies in three reviews (29, 8434,
1051), whilst the fourth found that stage I oligometa-
static NSCLC was associated with significant better sur-
vival than stage III–IV in 1/5 studies (237). One review
investigated the association between gross tumour vol-
ume and the prognosis of patients with unresectable
NSCLC after radiotherapy treatment. The overall sur-
vival was significantly less in patients with a large (≥ 112
cm3), compared to small (< 112 cm3), gross tumour vol-
ume (5489). A second review noted that tumour volume
was identified as a significant factor for stage III NSCLC
in two studies of multivariate analysis (8434).
Discussion
This paper provides an example of the development and
application of a pragmatic and innovative approach for
reviewing an extensive and complicated body of research
evidence to inform decision-making. The review aimed to
identify prognostic factors associated with lung cancer
survival. It focused on the findings of modifiable factors,
but also provided an overview of the evidence relating to
any prognostic factor, as well as a useful resource of all the
reviews and meta-analyses of broader prognostic research
questions. This was achieved using a three-staged review-
ing approach, which included an initial mapping review of
lung cancer prognostic research, based on titles and ab-
stracts, followed by an overview of systematic reviews
evaluating factors that independently contribute to lung
cancer survival. A compressive prognostic factor coding
scheme was developed as part of the mapping review,
from which a list of modifiable factors was drawn, based
on input from key stakeholders. The overview of reviews,
which was based on full text papers, aimed to provide a
description of the available reviews and their overall find-
ings. It provided both a summary of the prognostic factors
found to be associated with survival and a means of iden-
tifying the better quality and more recent reviews. It also
allowed us to assess whether there was consistency be-
tween the overall findings of multiple reviews assessing
the same prognostic factors. The quality of included re-
views was assessed using the eight essential criteria for a
systematic review [10, 11]. A more in-depth evaluation
was conducted of reviews that considered one or more
modifiable factors. This included further data extraction
including the magnitude of the effect and quality appraisal
using the AMSTAR checklist [30].
The reviewing approach was successful in providing a
systematic and transparent description of the nature and
coverage of an exceptionally broad prognostic research
field relating to lung cancer survival. It included an over-
view of more than 80 individual prognostic factors asso-
ciated with survival, with a special focus on 15
modifiable prognostic factors, such as critical patient
characteristics relevant to public health interventions
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ganisational and systemic healthcare redesign.
A well-conducted systematic review provides an essential
evidence resource for informing decision-making. However,
as highlighted by Ioannidis et al. and identified by our own
review, there is a massive production of unnecessary, mis-
leading, and conflicted systematic reviews [36]. A frequent
problem faced by decision-makers is the difficulty in inter-
preting the findings of multiple reviews reporting inconsist-
ent results and conclusions [21, 37]. A well-conducted
overview of reviews provides an objective assessment of
whether the conclusions of individual reviews are consistent
or not, as well highlighting the most relevant and high qual-
ity reviews. The identification of consistent findings across
multiple high-quality systematic reviews also provides more
confidence in the value of a prognostic factor. The current
reviewing approach was developed with this in mind.
Systematic mapping reviews and overview of reviews
can be viewed as rapid review approaches. The com-
bined stepped approach has far ranging applications for
present and future healthcare policy priorities with a
complicated epidemiology (e.g. other cancers and
chronic or degenerative conditions), where a review of
wide-ranging systematic reviews is needed in a relatively
short timeframe. Systematic mapping reviews are gener-
ally used to structure a broad research area, whilst sys-
tematic reviews tend to focus on gathering evidence to
answer a more focused research question. Both aim to
identify and summarise the evidence base in an object-
ive, repeatable, and transparent way. Where there is a
broad evidence base, prioritising evidence from system-
atic reviews limits unnecessary duplication, minimises
resources needed to screen and summarise primary level
evidence, and reduces potential bias and/or error, which
could be incurred by reviewing primary evidence rapidly
[38]. The advantage of using a staged approach is that it
provides a valuable description of the available research.
The inclusive nature of the mapping review enabled us
to identify both individual prognostic factors and reviews
that evaluated prognostic factors of specific interest,
which would have been excluded from a more focused
review. The staged approach also enabled us to recon-
sider reviews that evaluated prognostic factors deemed
to be important and modifiable by the stakeholders, but
did not meet the inclusion criteria for the overview of
reviews, in a transparent and objective way.
The initial mapping review (stage 1) and the overview
of reviews (stages 2–3) represent two consecutively
funded studies, each with a 9-month duration (1July
2015–31 March 2016 and 1 July 2016–31 March 2017).
The breadth and volume of the evidence base meant that
a conventional systematic review of primary studies was
not feasible within the overall timeframe. Furthermore,
although the primary focus was to identify individualcandidate prognostic factors (in prognostic factor re-
search), these are sometimes investigated within, or
alongside, other prognostic research studies. Our staged
reviewing approach, utilising existing reviews, enabled
us to complete both studies on time, whilst maintaining
the necessary breadth of the evidence review. However,
completing the entire review over 18 months still proved
very challenging. This was compounded by the fact that
the review was conducted by multiple reviewers working
part-time, most of whom worked only on the mapping
review (stage 1) or overview of reviews (stage 2–3). In
order to maintain consistency, there were weekly team
meetings, but on occasion, individual reviewers had to
suspend work until queries could be addressed at the
next meeting, or re-check work to ensure it was correct.
The volume of relevant systematic reviews was far more
than expected, and the fact that most of these were fairly
recent and poor quality meant that the time available for
a more in-depth review of modifying factors (stage 3)
was limited. The diversity and complexity of the evi-
dence base also made the review work challenging and
time consuming. The main challenge here, as well as the
large number of reviews, was that existing reviews varied
in terms of the methods used for searching and synthe-
sising the evidence. Furthermore, the primary studies
within each review also varied in terms of sample size,
population and lung cancer types, methods used to iden-
tify prognostic factors, the way in which the factors were
measured (as a continuous or binary measure), the
thresholds used to categorise the prognostic factors, and
the type of variables that were adjusted for in the ana-
lysis. In order to expedite the review, we increased the
number of reviewers working on it. This also brought its
challenges, as it required everyone to implement the
complicated inclusion criteria and coding schemes, with
much checking required to achieve consistency.
The rapid review approach was based on a narrative
synthesis and utilised the overall findings and conclu-
sions of the included reviews [31]. The magnitude of ef-
fect of prognostic factors was only considered for the
modifiable factors. However, the findings of most re-
views were based on either the statistical significance of
included studies or ‘vote counting’, neither of which is
capable of accurately evaluating the association with sur-
vival. A review of reviews generally relies on the ap-
praisal and data extraction of previous reviews rather
than going back to the primary sources [31]. Alterna-
tively, existing reviews can be used as a reference source
for identifying or selecting primary studies [31]. A po-
tential next stage of the rapid review approach presented
here could include utilising the results of the searches,
or data extraction, from a specified subset of included
systematic reviews to inform a new synthesis of primary
studies. This would enable a more in-depth evaluation
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by double counting of included studies, which could
occur in a meta-analysis of meta-analyses [39].
In capturing the breadth of the literature, we inevitably
lost depth and detail. Limiting inclusion to systematic re-
views means some modifiable factors investigated by pri-
mary studies but not covered by a systematic review may
have been missed. No findings were reported for 12/27
(44%) of the potentially modifiable factors identified from
the mapping review. Potential modifiable factors may have
been evaluated as part of a non-prognostic factor research
question, published as a non-English language publication
or conference abstract, or not deemed to be a systematic
review. Some studies retrieved in full were found, on in-
spection, not to meet the inclusion criteria.
The challenge of defining modifiable factors was a po-
tential limitation of our review. The decision on what con-
stitutes a modifiable factor is fairly subjective, and in order
to avoid excluding any potentially important modifiable
factors, we chose to consider all those identified by either
stakeholder. However, it could be argued that the list
should have been limited to those that are modifiable once
cancer has been diagnosed, thus excluding features of ex-
tensive disease which could, in theory, be modified but are
unlikely to change patient outcomes. The list used in our
review was based on limited input from only two clini-
cians. A more robust approach would have utilised expert
consensus methodology, for example, using a Delphi sur-
vey; however, this was not feasible within the confines of
the current project. Another potential limitation of our re-
view is the timing of the searches, which were conducted
at the end of 2015. However, our report was sufficient to
meet the needs of our stakeholders, and since we present
the review here as a methodological example, we did not
update the searches.
An important limitation of the included reviews, and
the available evidence base for the prognostic factors to
inform clinical practice, was the limited data presented
on histological subtypes. Many reviews focused on the
evolution of lung cancer as a whole and only reported
limited data on specific subtypes. Notably, three import-
ant and potentially useful modifiable factors were only
considered by systematic reviews that evaluated lung
cancer as a whole. Lung cancer is a heterogeneous dis-
ease, with different cell types growing and spreading dif-
ferently. The feasibility of having any impact on the
prognosis of lung cancer is dependent on tumour
growth rate and spread of the disease, and as such, re-
search studies lumping lung cancer types can be non-
informative for implementation in clinical practice. Even
lumping all NSCLC subtypes in one group can be non-
informative as shown in systematic review of the natural
history and growth rates of NSCLC, which found that the
data regarding the distribution of tumour volumedoubling time showed a wide spectrum of growth rates
[40]. However, we also acknowledge that the broad remit
of our review and the large number of included reviews
meant that we have also reported data according to the
broader categories of lung cancer types. Better reporting
of the findings relating to histological subtypes is required,
within both systematic reviews and primary studies.
Our review shows the large volume of systematic reviews
that have already been conducted, indicating the need for an
overview of current reviews, before yet another systematic
review of primary studies is considered. Our review also
shows that despite the enthusiasm for conducting systematic
reviews of prognostic factors for lung cancer, very few focus
on modifiable factors. A recent comprehensive analysis of
global lung cancer research conducted over a decade
(2004–2013) found that commitment to lung cancer re-
search has fallen in most countries apart from China, and
shows that it has no correlation with lung cancer burden
[41]. Our findings corroborate this in that most of the
reviews we identified were from China, yet interestingly,
only one of these reviews evaluated a potentially modifiable
factor (gross tumour volume), which could be argued to be
a feature of extensive disease rather than a modifiable factor.
Our review also highlights the limitations, in both volume
and quality, of the primary studies evaluating modifiable
factors.
The review identifies important gaps in the evidence base
and potential areas for future, more in-depth, focused sys-
tematic reviews. Most of the included reviews focused on
prognostic factors for NSCLC, and more reviews are likely
to be needed for prognostic factors relating to SCLC. How-
ever, better reporting of histological subtypes in primary
studies is required, in order to assist subsequent inclusion
in future reviews. Further research is also needed to define
modifiable factors. Future systematic reviews are likely
needed for the 15 potentially modifiable factors for which
no findings are reported in the current review.
Conclusions
The study provides an example of the successful develop-
ment and application of a novel approach to review the
extensive and complicated research on prognostic factors
to inform decision-making. It enabled us to develop a
summary of the evidence base that is directly relevant to
the stakeholders in an objective, repeatable, and transpar-
ent way. It also provides essential information for future
research. However, it also required extensive planning,
management, and ongoing reviewer training, which was
time-consuming.
The review identified a large volume of published system-
atic reviews and meta-analyses of prognostic and predictive
factors for lung cancer survival. These provide evidence for
a long list of prognostic factors, but interestingly, few were
evaluated by multiple reviews. Where multiple reviews did
Lewis et al. Systematic Reviews           (2019) 8:171 Page 17 of 18evaluate the same prognostic factors, their findings, on the
whole, were fairly consistent. The review identified several
potentially modifiable factors for lung cancer survival, which
could contribute to evidence-based initiatives to improve
lung cancer survival.
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